In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...
SAN ANTONIO — A new study strengthens the evidence that pathological complete response (pCR) is a good surrogate marker of longer-term efficacy in the neoadjuvant drug treatment of breast cancer. pCR, ...
Traditionally, test developers have used quantitative PCR (qPCR) to create highly specific laboratory-developed tests (LDTs). However, digital PCR (dPCR) is emerging as the preferred technology for ...
“Neoadjuvant treatment with 12 weeks of THP led to a pCR rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer at the time of surgery, compared to 33% for those with ...
Soura, the only tertiary care cancer treatment centre in Kashmir, is facing serious criticism from patients and healthcare ...
Out of the 386 regencies and mayoralties targeted by the Health Ministry, fewer than half are estimated to have public health ...
Hosted on MSN
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback